Newsroom | 70928 results

WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer Shares New Findings for NUBEQA for Cognitive Decline in Men with aPC Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held fr...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in oncology at scale by providing access to data, funding, and expertise to multidisciplinary teams around the world who seek t...

DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Tune Therapeutics, a leading epigenome editing company, presented new data today at the European Association for the Study of Liver (EASL) Congress in Barcelona, Spain, demonstrating the first clinical evidence of epigenetic silencing in hepatitis B virus (HBV). The oral presentation was delivered by Dr. Ed Gane, Professor of Medicine at the University of Auckland and world-renowned authority on HBV. The phase 1b/2a clinical trial evaluated the safety an...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically significant insights that close the gap between the time of order and delivery of insights. Representing a significant paradigm shift in precision oncology workflows, Tempus Preview offers preliminary results in the critical window between when a diagnostic test is or...

CARROLLTON, Ga.--(BUSINESS WIRE)--Tanner Health announces its go-live with Hyro, the leading Responsible AI Assistant Platform for health care....

BOSTON--(BUSINESS WIRE)--Foundation Medicine launches FoundationOne®MRD, a molecular residual disease (MRD) test....

WILMINGTON, Del.--(BUSINESS WIRE)--Residents of Delaware County will soon have a new option for around-the-clock emergency and inpatient care closer to home. In early June, ChristianaCare will open ChristianaCare Hospital, Aston, a neighborhood hospital designed to expand access to care in a growing region with increasing health care needs. Download photos. The hospital is expected to care for approximately 15,000 patients each year, or about 40 per day, and will provide 24/7 emergency care, in...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus has been building novel biological foundation models and agentic workflows by leveraging its more than 500 petabytes of rich, molecularly grounded data—more than 45 million total de-identified...